Alight (NYSE: ALIT) faces NYSE price deficiency, weighs reverse stock split
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Alight, Inc. has received a notice from the New York Stock Exchange that it is not in compliance with the NYSE’s continued listing standard requiring an average closing share price of at least $1.00. The company’s Class A common stock traded below this level over a consecutive 30 trading-day period ending March 20, 2026.
Alight has six months from March 24, 2026 to regain compliance and can do so if, on the last trading day of any calendar month during this period, its stock closes at or above $1.00 and also averages at least $1.00 over the prior 30 trading days. The company is considering options to cure the deficiency, including a reverse stock split subject to stockholder approval at its next annual meeting. Its shares will continue trading on the NYSE during the cure period, and the notice is not expected to affect ongoing business operations or SEC reporting.
Positive
- None.
Negative
- NYSE minimum price noncompliance and potential delisting risk – Alight’s Class A common stock averaged below $1.00 over 30 consecutive trading days, triggering an NYSE notice and a six‑month cure period, after which delisting is possible if compliance is not regained.
- Considering a reverse stock split to cure the deficiency – The company is evaluating a reverse stock split, subject to stockholder approval, which signals management may need structural measures to restore the share price to the NYSE’s minimum level.
Insights
Alight faces NYSE price deficiency, exploring a reverse split cure.
Alight, Inc. has fallen out of compliance with the NYSE’s minimum $1.00 average share price rule after trading below this threshold for 30 consecutive trading days. This price-based noncompliance raises the possibility of delisting if not cured within the exchange’s six‑month window.
The company states it intends to regain compliance and is evaluating alternatives, explicitly including a reverse stock split subject to stockholder approval at the next annual meeting. A reverse split consolidates shares to increase the per‑share price, but does not change overall equity value by itself.
During the cure period, Alight’s stock continues trading on the NYSE and management does not expect any direct impact on ongoing operations or SEC reporting. Actual outcomes will depend on future share price performance and any actions approved by stockholders to address the NYSE requirement.
8-K Event Classification
3 items: 3.01, 7.01, 9.01
3 items
Item 3.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Securities
The company received a delisting notice or transferred its listing to a different exchange.
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
__________________________________________
FORM 8-K
__________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 24, 2026
__________________________________________
Alight, Inc.
(Exact name of Registrant as Specified in Its Charter)
__________________________________________
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
| (Address of Principal Executive Offices) | (Zip Code) | |||||||
Registrant’s Telephone Number, Including Area Code: (224) 737-7000
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
__________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On March 24, 2026 , Alight, Inc. (the “Company” or “Alight”) received a written notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that it was not in compliance with the continued listing standard set forth in Section 802.01C of the NYSE’s Listed Company Manual (“Section 802.01C”), as the average closing price of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”), was less than $1.00 per share over a consecutive 30 trading-day period ending March 20, 2026. The Notice does not affect the Company’s ongoing business operations or its U.S. Securities and Exchange Commission reporting requirements and has no immediate impact on the listing of the Company’s Common Stock on the NYSE, subject to the Company’s compliance with the NYSE’s other continued listing requirements.
The Company has responded to the NYSE with respect to its commitment to cure the deficiency and that it is considering available alternatives including, but not limited to, a reverse stock split, subject to stockholder approval no later than at the Company’s next annual meeting of stockholders. Pursuant to Section 802.01C, the Company has a period of six months following the receipt of the Notice to regain compliance with the minimum share price requirement. The Company may regain compliance at any time during the six-month cure period if on the last trading day of any calendar month during the six-month cure period the Common Stock has a closing share price of at least $1.00 and an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of that month.
7.01 Regulation FD Disclosure.
As required by Section 802.01C, the Company issued a press release on March 27, 2026 announcing that it had received the notice from the NYSE described in Item 3.01 of this Current Report on Form 8-K (the “Report”) and that the Company intends to regain compliance.
A copy of this press release is furnished as Exhibit 99.1 to this Report. The information in Item 7.01 and Exhibit 99.1 of this Report is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits.
| Exhibit No. | Description | |||||||
| 99.1 | Press Release of the Company dated as of March 27, 2026 | |||||||
| 104 | The cover page from the Current Report on Form 8-K formatted in Inline XBRL. | |||||||
Forward-Looking Statements
This Report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, Company’s intentions regarding regaining compliance with the minimum price condition of NYSE and the Company’s intended methods to cure such related deficiency. In some cases, these forward-looking statements can be identified by the use of words such as “outlook,” “believes,” “expects,” “potential,” “continues,” “may,” “will,” “would,” “should,” “could,” “seeks,” “projects,” “predicts,” “intends,” “plans,” “estimates,” “anticipates” or the negative version of these words or other comparable words. Such forward-looking statements are subject to various risks and uncertainties including those described in the forward-looking statements can be found under the section entitled “Risk Factors” of Alight’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the “SEC”) on February 24, 2026, as such factors may be updated from time to time in Alight's filings with the SEC, which are, or will be, accessible on the SEC's website at www.sec.gov. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. These factors should not be construed as exhaustive and should be considered along with other factors noted in Alight’s filings with the SEC. Alight undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Alight, Inc. | |||||||||||
| Date: | March 27, 2026 | By: | /s/ Martin Felli | ||||||||
| Martin Felli, Chief Legal Officer and Corporate Secretary | |||||||||||
Exhibit 99.1
Alight Commits to Remain on NYSE After Receiving Continued Listing Standard Notice
The Company’s common stock continues to trade on the NYSE under symbol “ALIT”
CHICAGO—March 27, 2026—Alight, Inc. (NYSE: ALIT), a leading benefits administration provider of health, wealth, leave and point solutions, announced that on March 24, 2026, it received written notice from the New York Stock Exchange (the “NYSE”) that it is not in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company’s Class A common stock was less than $1.00 per share over the consecutive 30 trading-day period ended March 20, 2026.
Alight has responded to the NYSE with respect to its commitment to regain compliance with Rule 802.01C and remain listed on the NYSE. The Company is considering all options to regain compliance with the NYSE’s continued listing standards, including, but not limited to, a reverse stock split, subject to stockholder approval no later than at the Company’s next annual meeting of stockholders.
The Company can regain compliance at any time within a six-month cure period following its receipt of the NYSE notice if, on the last trading day of any calendar month during such cure period, the Company’s Class A common stock has both: (i) a closing share price of at least $1.00 and (ii) an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of the applicable calendar month.
There is no immediate direct impact on the listing of Alight’s Class A common stock, which will continue to trade on the NYSE during the cure period, subject to the Company’s compliance with the NYSE’s other continued listing requirements.
Furthermore, the notice is not anticipated to impact the ongoing business operations of the Company or its reporting requirements with the U.S. Securities and Exchange Commission.
About Alight Solutions
Alight is a leading benefits administration provider of health, wealth, leave and point solutions for many of the world’s largest organizations and over 30 million people. Through the administration of employee benefits, Alight helps clients gain a benefits advantage while building a healthy and financially secure workforce by unifying the benefits ecosystem across health, wealth, wellbeing, absence management and navigation. Our Alight Worklife® platform empowers employers to gain a deeper understanding of their workforce and engage them throughout life’s most important moments with personalized benefits management and data-driven insights, leading to increased employee wellbeing, engagement and productivity. Learn more at alight.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934,
as amended. These statements include, but are not limited to, the Company’s intentions regarding regaining compliance with the minimum price condition of NYSE and remaining listed on the NYSE and the Company’s intended methods to cure such related deficiency. In some cases, these forward-looking statements can be identified by the use of words such as “outlook,” “believes,” “expects,” “potential,” “continues,” “may,” “will,” “would,” “should,” “could,” “seeks,” “projects,” “predicts,” “intends,” “plans,” “estimates,” “anticipates” or the negative version of these words or other comparable words. Such forward-looking statements are subject to various risks and uncertainties including those described in the forward-looking statements can be found under the section entitled “Risk Factors” of Alight’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on February 24, 2026, as such factors may be updated from time to time in Alight's filings with the SEC, which are, or will be, accessible on the SEC's website at www.sec.gov. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. These factors should not be construed as exhaustive and should be considered along with other factors noted in Alight’s filings with the SEC. Alight undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.
Contacts
Investors:
investor.relations@alight.com
Media:
Mariana Fischbach
mariana.fischbach@alight.com
FAQ
What NYSE rule did Alight (ALIT) fail to satisfy?
Alight failed to satisfy NYSE Section 802.01C, which requires an average closing share price of at least $1.00. Its Class A common stock traded below this level over a consecutive 30 trading-day period ended March 20, 2026, prompting a noncompliance notice.
Does the NYSE notice immediately affect trading in Alight (ALIT) stock?
The notice does not immediately affect trading. Alight’s Class A common stock continues to trade on the NYSE during the six-month cure period, as long as the company meets the exchange’s other continued listing requirements and works to regain price compliance.
How can Alight (ALIT) regain compliance with the NYSE price standard?
Alight can regain compliance at any time during the six-month cure period if, on the last trading day of any calendar month, its stock closes at or above $1.00 and also has an average closing price of at least $1.00 over the prior 30 trading days.
Is Alight (ALIT) planning a reverse stock split to stay listed?
Alight is considering a reverse stock split as one option to cure the deficiency. Any reverse split would be subject to stockholder approval no later than the company’s next annual meeting, and is one of several alternatives under evaluation.
Will the NYSE noncompliance notice affect Alight’s (ALIT) operations or SEC reporting?
The company states the notice is not anticipated to impact ongoing business operations or its reporting obligations with the U.S. Securities and Exchange Commission. The issue relates specifically to the NYSE’s minimum share price listing standard, not operational performance.
What happens if Alight (ALIT) does not regain NYSE compliance within six months?
If Alight does not regain compliance within the six-month cure period, the NYSE could begin delisting procedures under its rules. The company’s stated goal is to regain compliance and remain listed, including by considering structural options such as a reverse stock split.
Filing Exhibits & Attachments
4 documents
Alight Inc.